NEW YORK (GenomeWeb News) – OncoMethylome Sciences said today that it will provide MGMT gene promoter methylation testing services for Merck KGaA’s clinical trial program for cilengitide, a drug being developed for glioblastoma multiforme treatment.
 
As part of the agreement, Germany’s Merck also gained a worldwide, non-exclusive license to use the results from the methylation assay for optimizing cilengitide treatment.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.